The Fort Worth Press - Frenchman rewarded for lifetime of research into narcolepsy

USD -
AED 3.672503
AFN 62.999722
ALL 83.250299
AMD 377.459541
ANG 1.790083
AOA 917.000269
ARS 1396.262205
AUD 1.406153
AWG 1.8
AZN 1.702594
BAM 1.694705
BBD 2.008318
BDT 122.350128
BGN 1.709309
BHD 0.377507
BIF 2960.600993
BMD 1
BND 1.274164
BOB 6.904306
BRL 5.193199
BSD 0.997141
BTN 92.081275
BWP 13.550819
BYN 2.990815
BYR 19600
BZD 2.005372
CAD 1.369037
CDF 2264.999974
CHF 0.784705
CLF 0.022981
CLP 907.409805
CNY 6.88685
CNH 6.88185
COP 3701.14
CRC 467.377177
CUC 1
CUP 26.5
CVE 97.149527
CZK 21.16085
DJF 177.558271
DKK 6.474425
DOP 60.861277
DZD 132.077565
EGP 52.251214
ERN 15
ETB 157.000068
EUR 0.86642
FJD 2.20805
FKP 0.751829
GBP 0.748435
GEL 2.710033
GGP 0.751829
GHS 10.884974
GIP 0.751829
GMD 73.499785
GNF 8738.4866
GTQ 7.653371
GYD 209.039327
HKD 7.83725
HNL 26.570299
HRK 6.527104
HTG 130.795692
HUF 336.835504
IDR 16964.25
ILS 3.09945
IMP 0.751829
INR 92.39125
IQD 1310
IRR 1314000.000159
ISK 124.420233
JEP 0.751829
JMD 156.858158
JOD 0.709038
JPY 158.865014
KES 129.550256
KGS 87.450153
KHR 4001.403697
KMF 426.999748
KPW 900.043905
KRW 1486.090231
KWD 0.30667
KYD 0.830947
KZT 480.450219
LAK 21397.625856
LBP 89443.965349
LKR 310.510354
LRD 182.47119
LSL 16.689777
LTL 2.95274
LVL 0.60489
LYD 6.395004
MAD 9.36375
MDL 17.394507
MGA 4165.000213
MKD 53.423868
MMK 2100.153228
MNT 3574.497589
MOP 8.048436
MRU 40.105027
MUR 46.619679
MVR 15.44942
MWK 1736.99969
MXN 17.651635
MYR 3.917005
MZN 63.909805
NAD 16.689599
NGN 1352.87964
NIO 36.719505
NOK 9.578495
NPR 147.330387
NZD 1.706095
OMR 0.384496
PAB 0.99918
PEN 3.417501
PGK 4.30075
PHP 59.809751
PKR 279.250341
PLN 3.69215
PYG 6463.911273
QAR 3.643502
RON 4.413503
RSD 101.777007
RUB 82.373582
RWF 1459
SAR 3.754447
SBD 8.045182
SCR 14.272963
SDG 601.000071
SEK 9.275299
SGD 1.27605
SHP 0.750259
SLE 24.575981
SLL 20969.510825
SOS 568.841522
SRD 37.625007
STD 20697.981008
STN 21.225904
SVC 8.724509
SYP 110.875895
SZL 16.690088
THB 32.320032
TJS 9.557442
TMT 3.51
TND 2.932498
TOP 2.40776
TRY 44.217599
TTD 6.765416
TWD 31.896843
TZS 2608.729779
UAH 43.810415
UGX 3771.52085
UYU 40.615395
UZS 12137.498289
VES 447.80816
VND 26300
VUV 119.587146
WST 2.754209
XAF 568.371025
XAG 0.012542
XAU 0.0002
XCD 2.70255
XCG 1.797064
XDR 0.706871
XOF 570.500193
XPF 103.849931
YER 238.550133
ZAR 16.67759
ZMK 9001.196875
ZMW 19.448921
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • CMSC

    -0.0400

    22.95

    -0.17%

  • RYCEF

    0.3800

    16.5

    +2.3%

  • BCE

    0.1100

    26.01

    +0.42%

  • NGG

    -0.4700

    90.42

    -0.52%

  • JRI

    -0.0800

    12.46

    -0.64%

  • CMSD

    -0.0700

    22.88

    -0.31%

  • GSK

    -0.3600

    53.41

    -0.67%

  • RIO

    -0.0600

    89.8

    -0.07%

  • BCC

    1.2000

    72.92

    +1.65%

  • RELX

    -0.1800

    34.29

    -0.52%

  • VOD

    0.1500

    14.75

    +1.02%

  • BP

    0.9500

    43.85

    +2.17%

  • AZN

    -0.7200

    191.29

    -0.38%

  • BTI

    -0.3900

    60.55

    -0.64%

Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Frenchman rewarded for lifetime of research into narcolepsy

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

T.Harrison--TFWP